The AIDS Clinical Trials Group (ACTG) will present 29 presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023. The studies focus on COVID-19, HIV cure, pathogenesis, treatment, long-term complications, tuberculosis, hepatitis C, and contraception.
The Do IT Study assesses switching from INSTIs and TAF-containing regimens to doravirine-based treatments for weight gain reduction. The study aims to inform better strategies for managing ARV side effects in people living with HIV.
A recent study by the AIDS Clinical Trials Group found that nearly half of participants had atherosclerotic plaque in their coronary arteries, despite being considered at low-to-moderate risk. The study also revealed an association between plaque presence and higher levels of inflammation independent of traditional risk scores.
The ACTG announced that the Camostat treatment group in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial will not move to phase 3. The phase 2 data failed to meet criteria for graduation, based on demonstrating early changes in viral shedding or improvement in symptoms.
The AIDS Clinical Trials Group (ACTG) is commemorating its 40th anniversary by convening a virtual annual meeting. The group has played a critical role in HIV research for nearly four decades, conducting landmark studies that have changed the treatment and care of people living with HIV around the world.
The AIDS Clinical Trials Group (ACTG) has launched A5386, a phase 1 HIV cure study assessing the safety and efficacy of N-803 in conjunction with broadly neutralizing antibodies. The study aims to evaluate the immune system's ability to control HIV reservoirs and virus rebound.
The AIDS Clinical Trials Group (ACTG) has added BMS-986414 and BMS-986413, two monoclonal antibodies, to the ACTIV-2 outpatient treatment study for COVID-19. The combination therapy aims to improve efficacy, cover multiple variants, and reduce resistance. Participants will receive subcutaneous injections of the antibodies or placebo.